Physician profile
David P Mason
NPI 1215953567
$1,360.20
in general payments reported to CMS, 2019-2025
13 companies · $187 in 2025
The $187 reported for 2025 was more than what 81% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $44.24 · 2021: $28.06 · 2023: $354 · 2024: $245 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $765.82 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $401.72 | 2021-2025 | |
| Amgen INC. | $213.00 | 2019 | |
| Vapotherm INC | $200.48 | 2019-2024 | Vapotherm |
| Janssen Pharmaceuticals, INC | $158.64 | 2020-2024 | Xarelto |
| Csl Behring | $124.16 | 2019-2024 | Kcentra |
| Astrazeneca Pharmaceuticals LP | $104.32 | 2023 | Andexxa |
| Pfizer INC. | $52.18 | 2019-2020 | |
| Ethicon US, LLC | $34.90 | 2025 | Dermabond, Echelon; Endopath |
| Grifols USA, LLC | $16.44 | 2019 | |
| Janssen Biotech, INC. | $15.69 | 2021 | |
| Gilead Sciences, INC. | $14.85 | 2024 | |
| Shire North American Group INC | $12.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.